DexCom (DXCM)
(Delayed Data from NSDQ)
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.22 -0.02 (-0.03%) 6:08 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.22 -0.02 (-0.03%) 6:08 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Zacks News
Quest Diagnostics' (DGX) Haystack Oncology Inks New Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX), which is led by growth with recovery in procedural volumes and acceleration from new business lines.
Why DexCom (DXCM) Dipped More Than Broader Market Today
by Zacks Equity Research
DexCom (DXCM) reachead $122.59 at the closing of the latest trading day, reflecting a -0.41% change compared to its last close.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.
Neogen (NEOG) to Advance Feline DNA Testing With New Pact
by Zacks Equity Research
Neogen's (NEOG) strategic alliance will expand feline DNA testing and strengthen its relationship with the kitty community.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.
Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger
by Zacks Equity Research
Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.
Align Technologies (ALGN) Secures Updated Medical Device License
by Zacks Equity Research
Align Technologies' (ALGN) Invisalign Palatal Expander system receives an updated medical device license from Health Canada.
Here's Why You Should Buy Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.
Tandem Diabetes (TNDM) Avails Tandem Source in the United States
by Zacks Equity Research
Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.
Integra (IART) to Advance ENT Division With New Buyout Deal
by Zacks Equity Research
Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.
Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.
Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes
by Zacks Equity Research
Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Reasons to Retain Baxter International (BAX) in Your Portfolio
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Medtronic (MDT) Expands AI-Driven Care With New Partnership
by Zacks Equity Research
Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.
QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes
by Zacks Equity Research
QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.
Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space
by Zacks Equity Research
Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.
Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.